Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
4Statement of changes in beneficial ownership of securitiesSep 19, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesSep 19, 2017View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventAug 11, 2017View HTMLDownload DOCDownload PDFDownload XLS
424B5Form of prospectus disclosing information facts events covered in both forms 424B2 424B3Aug 9, 2017View HTMLDownload DOCDownload PDFDownload XLS
FWPFree Writing ProspectusAug 9, 2017View HTMLDownload DOCDownload PDFDownload XLS
424B5Form of prospectus disclosing information facts events covered in both forms 424B2 424B3Aug 8, 2017View HTMLDownload DOCDownload PDFDownload XLS
305B2Initial statement filed pursuant to the Trust Indenture ActAug 8, 2017View HTMLDownload DOCDownload PDFDownload XLS
10-QQuarterly report which provides a continuing view of a company's financial positionAug 2, 2017View HTMLDownload DOCDownload PDFDownload XLSView XBRLDownload XBRL
8-KReport of unscheduled material events or corporate eventAug 2, 2017View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 27, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJun 23, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJun 20, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJun 20, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJun 13, 2017View HTMLDownload DOCDownload PDF
S-8 POSPost-effective amendment to an S-8 filingJun 13, 2017View HTMLDownload DOCDownload PDFDownload XLS
S-8 POSPost-effective amendment to an S-8 filingJun 13, 2017View HTMLDownload DOCDownload PDFDownload XLS
S-8 POSPost-effective amendment to an S-8 filingJun 13, 2017View HTMLDownload DOCDownload PDFDownload XLS
S-8Securities offered to employees pursuant to employee benefit plansJun 13, 2017View HTMLDownload DOCDownload PDFDownload XLS
S-8 POSPost-effective amendment to an S-8 filingJun 13, 2017View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventJun 12, 2017View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 9, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJun 8, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJun 8, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJun 8, 2017View HTMLDownload DOCDownload PDF
4Statement of changes in beneficial ownership of securitiesJun 8, 2017View HTMLDownload DOCDownload PDF
1-25      26-50      51-75      76-100      101-125      126-134

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information